Download PDF
CC BY-NC-ND 4.0 · International Journal of Epilepsy 2017; 04(01): 059-064
DOI: 10.1016/j.ijep.2017.04.001
Bone Health
Thieme Medical and Scientific Publishers Private Ltd.

Bone health in epilepsy

Bindu Menon
a   Department of Neurology, Apollo Speciality hospital Nellore, India
,
Man Mohan Mehndiratta
b   Janakpuri Super Speciality Hospital, New Delhi, India
› Author Affiliations
Further Information

Publication History

Received: 09 August 2016

Accepted: 07 April 2017

Publication Date:
06 May 2018 (online)

   Permissions and Reprints

Abstract

Epilepsy is one of the most common neurological disorder usually requiring life long treatment. Long term treatment with antiepileptic drugs (AED’s) is associated with chronic side effects which includes effect on bone health

There is a growing volume of literature suggesting that chronic use of AED in patients with epilepsy significantly reduces bone mineral density (BMD) with an increased fracture risk. The causes of these associations are likely to be multifactorial. Unlike other chronic side effects, symptoms of bone loss are insidious and asymptomatic; hence they are usually not recognized, and thus untreated. Hence one needs to determine the presence of osteoporosis before the overt signs are evident to reduce fracture risk. Evaluation of bone health is mandatory for a comprehensive treatment and to provide calcium and 25-OH vitamin-D 3 supplementation if needed. The goals of epilepsy treatment are to achieve seizure freedom while minimizing adverse effects of treatment. Management goal should include a comprehensive care of the patient and this includes much more than controlling seizures.

Keywords

Antiepileptic drugs - Bone health
 

  • References

  • 1 Hahn TJ, Hendin BA, Scharp CR. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 287 1972; 900-904
    CrossrefPubMedGoogle Scholar
  • 2 Richens A, Rowe DFJ. Disturbance of calcium metabolism by anticonvulsant drugs. Br Med J 4 1970; 73-76
    CrossrefPubMedGoogle Scholar
  • 3 Tolman KG, Jubiz W, Sannella JJ. et al. Osteomalacia associated with anticonvulsant drug therapy in mentally retarded children. Pediatrics 56 1975; 45-51
    PubMedGoogle Scholar
  • 4 Hahn TJ, Hendin BA, Scharp CR, Boisseau VC. Haddad JG: Serum 25- hydroxycalciferol levels and bone mass in children on chronic anticonvulsant therapy. N Engl J Med 292 1975; 550-553
    CrossrefPubMedGoogle Scholar
  • 5 Christiansen C, Rodbro P, Lund M. Incidence of anticonvulsant osteomalacia and effect of vitamin D: controlled therapeutic trial. BMJ 4 1973; 695-701
    CrossrefPubMedGoogle Scholar
  • 6 Mosekilde L, Christensen SC, Lund B, Sorensen OH, Melsen F. The interrelationships between serum 25-hydroxycholcalciferol, serum parathyroid hormone and bone changes in anticonvulsant osteomalacia. Acta Endocrinol 84 1977; 559-565
    PubMedGoogle Scholar
  • 7 Sotaniemi EA, Hakkarainen HK, Puranen JA, Lahti RO. Radiologic bone changes and hypocalcemia with anticonvulsant therapy in epilepsy. Ann Intern Med 77 1972; 389-394
    CrossrefPubMedGoogle Scholar
  • 8 Holick MF, Krane SM. Introduction to bone and mineral metabolism. Eugene B, Fauci A, Kasper D, Hauser S, Longo D, Jameson JL. Harrison's Principles of Internal Medicine. In Harrison's Principles of Internal Medicine. 15th ed.. 2001. McGraw-Hill; New York: 2192-2194
    Google Scholar
  • 9 Garn SM. The Earlier Gain and the Later Loss of Cortical Bone: Nutritional Perspective. 1970. C.C Thomas; Springfield, IL:
    Google Scholar
  • 10 Bouillon R, Reynaert J, Claes JH, Lissens W, De Moor P. The effect of anticonvulsant therapy on serum levels of 25-hydroxyvitamin D, calcium, and parathyroid hormone. J Clin Endocrinol Metab 41 1975; 1130-1135
    CrossrefPubMedGoogle Scholar
  • 11 Berry JL, Mawer EB, Walker DA, Carr P, Adams PH. Effect of antiepileptic drug therapy and exposure to sunlight on vitamin D status in institutionalized patients. Oxley J, Janz J, Meinardi H. Antiepileptic Therapy: Chronic Toxicity of Antiepileptic Drugs. 1983. Raven Press; 185-192
    Google Scholar
  • 12 Gough H, Goggin T, Bissessar A, Baker M, Crowley M, Callaghan N. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in outpatients with epilepsy. Q J Med 230 1986; 569-577
    PubMedGoogle Scholar
  • 13 Hoikka V, Callaghan N. Biochemical evidence for osteomalacia with carbamazepine therapy. Acta Neurol Scand 62 1980; 282-286
    PubMedGoogle Scholar
  • 14 Bogliun G, Beghi E, Crespi V, Delodovici L, d'Amico P. Anticonvulsant drugs and bone metabolism. Acta Neurol Scand 74 1986; 284-288
    PubMedGoogle Scholar
  • 15 Andress DL, Ozuna J, Tirschwell D. et al. Antiepileptic drug-induced bone loss in young male patients who have seizures. Arch Neurol 59 2002; 781-786
    CrossrefPubMedGoogle Scholar
  • 16 Skillen AW, Peirides AM. Serum gamma glutamyl transferase and alkaline phosphatase activities in epileptics receiving anticonvulsant therapy. Clin Chim Acta 72 1976; 245-251
    CrossrefPubMedGoogle Scholar
  • 17 Stamp TCB, Round JM, Haddad JG. Plasma levels and therapeutic effect of 25-hydroxycholecalciferol in epileptic patients taking anticonvulsant drugs. Br Med J 4 1972; 9-12
    CrossrefPubMedGoogle Scholar
  • 18 Tjellesen L, Christiansen C. Serum vitamin D metabolites in epileptic patients treated with 2 different anticonvulsants. Acta Neurol Scand 66 1982; 335-341
    PubMedGoogle Scholar
  • 19 Sato Y, Kondo I, Ishida S. et al. Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology 57 2001; 445-449
    CrossrefPubMedGoogle Scholar
  • 20 Weinstein RS, Bryce GF, Sappington LJ, King DW, Gallagher BB. Decreased serum ionized calcium and normal vitamin D metabolite levels with anticonvulsant drug treatment. J Clin Endocrinol Metab 58 1984; 1003-1009
    CrossrefPubMedGoogle Scholar
  • 21 Valimaki MJ, Tiihonen M, Laitinen K. et al. Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on anti-epileptic drugs. J Bone Miner Res 9 1994; 631-637
    PubMedGoogle Scholar
  • 22 O'Hare JA, Duggan B, O'Driscoll D, Callaghan N. Biochemical evidence for osteomalacia with carbamazepine therapy. Acta Neurol Scand 62 1980; 282-286
    PubMedGoogle Scholar
  • 23 Okesina AB, Donaldson D, Lascelles PT. Isoenzymes of alkaline phosphatase in epileptic patients receiving carbamazepine monotherapy. J Clin Pathol 44 1991; 480-482
    CrossrefPubMedGoogle Scholar
  • 24 Takeshita N, Seino Y, Ishida H. et al. Increased circulating levels of gamma-carboxyglutamic acid-containing protein and decreased bone mass in children on anticonvulsant therapy. Calcif Tissue Int 44 1989; 80-85
    CrossrefPubMedGoogle Scholar
  • 25 Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F. Increased bone turnover in epileptic patients treated with carbamazepine. Ann Neurol 47 2000; 385-388
    CrossrefPubMedGoogle Scholar
  • 26 Verrotti A, Greco R, Latini G, Morgese G, Chiarelli F. Increased bone turnover in prepubertal, pubertal, and postpubertal patients receiving carbamazepine. Epilepsia 43 2002; 1488-1492
    CrossrefPubMedGoogle Scholar
  • 27 Recommended dietary allowances for macronutrients. Dietary Guidelines for Indians—A Manual. 2017. National Institute of Nutrition ICMR; 2011: 89
    Google Scholar
  • 28 Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. 2010. National Academy Press; Washington, DC:
    Google Scholar
  • 29 Menon Bindu, Harinarayan ChittariVenkata, Raj MarellaNeelima, Vemuri Swapna, Himabindu G, Afsana TK. Prevalence of low dietary calcium intake in patients with epilepsy: a study from South India. Neurol India 58 2010; 209-212
    CrossrefPubMedGoogle Scholar
  • 30 Koppel BS, Harden CL, Nikolov BG, Labar DR. An analysis of lifetime fractures in women with epilepsy. Acta Neurol Scand 111 2005; 225-228
    CrossrefPubMedGoogle Scholar
  • 31 Sheth RD, Gidal BE, Hermann BP. Pathological fractures in epilepsy. Epilepsy Behav 9 2006; 601-605
    CrossrefPubMedGoogle Scholar
  • 32 Vestergaard P, Tigaran S, Rejnmark L, Tigaran C, Dam M, Mosekilde L. Fracture risk is increased in epilepsy. Acta Neurol Scand 99 1999; 269-275
    CrossrefPubMedGoogle Scholar
  • 33 Souverein PC, Webb DJ, Petri H, Weil J, Van Staa TP, Egberts T. Incidence of fractures among epilepsy patients: a population-based retrospective cohort study in the General Practice Research Database. Epilepsia 46 2005; 304-310
    CrossrefPubMedGoogle Scholar
  • 34 Persson HB, Alberts KA, Farahmand BY, Tomson T. Risk of extremity fractures in adult outpatients with epilepsy. Epilepsia 43 2002; 768-772
    CrossrefPubMedGoogle Scholar
  • 35 Appleton RE. Seizure-related injuries in children with newly diagnosed and untreated epilepsy. Epilepsia 43 2002; 764-767
    CrossrefPubMedGoogle Scholar
  • 36 Petty SJ, Paton LM, O'Brien TJ. et al. Effect of antiepileptic medication on bone mineral measures. Neurology 65 2005; 1358-1365
    CrossrefPubMedGoogle Scholar
  • 37 Farhat G, Yamout B, Mikati MA, Demirjian S, Sawaya R, El-Hajj Fuleihan G. Effect of antiepileptic drugs on bone density in ambulatory patients. Neurology 58 2002; 1348-1353
    CrossrefPubMedGoogle Scholar
  • 38 Pack AM. Falls and fractures in patients with epilepsy Is there an increased risk? If so, why?. Neurology 79 2012; 119-120
    CrossrefPubMedGoogle Scholar
  • 39 Ensrud KE, Walczak TS, Blackwell T, Ensrud ER, Bowman PJ, Stone KL. Antiepileptic drug use increases rates of bone loss in older women: a prospective study. Neurology 62 2004; 2051-2057
    CrossrefPubMedGoogle Scholar
  • 40 Nicholas JM, Ridsdale L, Richardson MP, Grieve AP, Gulliford MC. Fracture risk with use of liver enzyme inducing antiepileptic drugs in people with active epilepsy: cohort study using the general practice research database. Seizure 22 2013; 37-42
    CrossrefPubMedGoogle Scholar
  • 41 Shen Chunhong, Chen Feng, Zhang Yinxi, Guo Yi, Ding Meiping. Association between use of antiepileptic drugs and fracture risk: a systematic review and meta-analysis. Bone 64 2014; 246-253
    CrossrefPubMedGoogle Scholar
  • 42 Fitzpatrick LA. Pathophysiology of bone loss in patients receiving anticonvulsant therapy. Epilepsy Behav 5 (02) 2004; S3-15
    PubMedGoogle Scholar
  • 43 Hamersvelt HW. Brains and bones. Nephrol Dial Transplant 13 1998; 801-802
    CrossrefPubMedGoogle Scholar
  • 44 Sheth RD, Wesolowski CA, Jacob JC. et al. Effect of carbamazapine and valproate on bone mineral density. J Pediatr 127 1995; 256-262
    CrossrefPubMedGoogle Scholar
  • 45 Chung S, Ahn C. Effects of anti-epileptic drug therapy on bone mineral density in ambulatory epileptic children. Brain Dev 16 1994; 382-385
    CrossrefPubMedGoogle Scholar
  • 46 Koch HV, Kratf D, von Herrath D. Influence of diphenylhydantoin and phenobarbital on intestinal calcium transport in the rat. Epilepsia 13 1972; 829-841
    CrossrefPubMedGoogle Scholar
  • 47 Zhou C, Assem M, Tay JC. et al. Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia. J Clin Invest 116 2006; 1703-1712
    CrossrefPubMedGoogle Scholar
  • 48 Tomita S, Ohnishi JI, Nakano M, Ichikawa Y. The effect of anticonvulsant drugs on vitamin D3-activating cytochrome P-450-linked monooxygenase system. J Steroid Biochem Mol Biol 39 1991; 479-485
    CrossrefPubMedGoogle Scholar
  • 49 Theodoropoulos C, Demers C, Mirshahi A, Gascon-Barre M. 1, 25-dihydroxy D3 down regulates the rat intestinal vitamin D3-25 hydroxylase CYP27A. Am J Physiol 281 2001; E315-25
    PubMedGoogle Scholar
  • 50 Holick MF. Stay tuned to PXR: an orphan actor that may not be D-structive only to bone. J Clin Invest 115 2005; 32-34
    CrossrefPubMedGoogle Scholar
  • 51 Takahashi A, Onodera K, Shinoda H, Mayanagi H. Phenytoin and its metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, show bone resorption in cultured neonatal mouse calvaria. Jpn J Pharmacol 82 2000; 82-84
    CrossrefPubMedGoogle Scholar
  • 52 Vernillo AT, Rifkin BR, Hauschka PV. Phenytoin affects osteoblastic secretion from osteoblastic rat osteosarcoma 17/2.8 cells in culture. Bone 11 1990; 309-312
    CrossrefPubMedGoogle Scholar
  • 53 Kruse K, Suss A, Busse M, Schneider P. Monomeric serum calcitonin and bone turnover during anticonvulsant treatment and in congenital hypothyroidism. J Pediatr 111 1987; 57-63
    CrossrefPubMedGoogle Scholar
  • 54 Pack AM, Morrell MJ, Randall A, McMahon DJ, Shane E. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 70 2008; 1586-1593
    CrossrefPubMedGoogle Scholar
  • 55 Davie MW, Emberson CE, Lawson DE. et al. Low plasma 25-hydroxyvitamin D and serum calcium in institutionalized epileptic subjects: associated risk factors, consequences and response to treatment with vitamin D. Q J Med 205 1983; 79-91
    PubMedGoogle Scholar
  • 56 Kafali G, Erscelan T, Tanzer F. Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years. Clin Pediatr 38 1999; 93-98
    CrossrefPubMedGoogle Scholar
  • 57 Sheth RD, Wesolowski CA, Jacob JC. et al. Effect of carbamazapine and valproate on bone mineral density. J Pediatr 127 1995; 256-262
    CrossrefPubMedGoogle Scholar
  • 58 Stephen LJ, McLellan AR, Harrison JH. et al. Bone density and antiepileptic drugs: a case controlled study. Seizure 8 1999; 339-342
    CrossrefPubMedGoogle Scholar
  • 59 Guo C, Ronen GM, Atkinson SA. Long-term valproate and lamotrigine treatment may be a marker for reduced growth and bone mass in children with epilepsy. Epilepsia 42 2001; 1141-1147
    PubMedGoogle Scholar
  • 60 Sheth RD, Hermann BP. Bone mineral density with lamotrigine monotherapy for epilepsy. Pediatr Neurol 37 2007; 250-254
    CrossrefPubMedGoogle Scholar
  • 61 Ensrud KE, Walczak TS, Blackwell TL, Ensrud ER, Barrett-Connor E, Orwoll ES. Osteoporotic Fractures in Men (MrOS) Study Research Group: antiepileptic drug use and rates of hip bone loss in older men: a prospective study. Neurology 71 (10) 2008; 723-730
    CrossrefPubMedGoogle Scholar
  • 62 Menon B, Harinarayan CV. The effect of anti-epileptic drug therapy on serum 25-hydroxyvitamin D and parameters of calcium and bone metabolism—A longitudinal study. Seizure 19 2010; 153-158
    CrossrefPubMedGoogle Scholar
  • 63 Hakami T, O'Brien TJ, Petty SJ. et al. Monotherapy with levetiracetam versus older AEDs: a randomized comparative trial of effects on bone health. Calcif Tissue Int 98 2016; 556-565
    CrossrefPubMedGoogle Scholar
  • 64 Artemiadis AK, Lambrinoudaki I, Voskou P, Tsivgoulis G, Safouris A. Bougea A, etal. Preliminary evidence for gender effects of levetiracetam monotherapy duration on bone health of patients with epilepsy. Epilepsy Behav 55 2016; 84-86
    CrossrefPubMedGoogle Scholar
  • 65 Vestergaard P. Effects of antiepileptic drugs on bone health and growth potential in children with epilepsy. Paediatr Drugs 17 2015; 141-150
    CrossrefPubMedGoogle Scholar
  • 66 Sheth RD, Binkley N, Hermann BP. Gender differences in bone mineral density in epilepsy. Epilepsia 49 2008; 125-131
    CrossrefPubMedGoogle Scholar
  • 67 Lin CM, Fan HC, Chao TY. et al. Potential effects of valproate and oxcarbazepine on growth velocity and bonemetabolism in epileptic children- a medical center experience. BMC Pediatr 3 2016; 61
    PubMedGoogle Scholar
  • 68 Serin HM, Koç ZP, Temelli B, Esen İ. The bone mineral content alterations in pediatric patients medicated with levetiracetam, valproic acid, and carbamazepine. Epilepsy Behav 51 2015; 221-224
    CrossrefPubMedGoogle Scholar
  • 69 Fong CY, Kong AN, Poh BK. et al. Vitamin D deficiency and its risk factors in Malaysian children with epilepsy. Epilepsia. July 2016 10.1111/epi.13443 [Epubaheadofprint]
    PubMedGoogle Scholar
  • 70 Mikati MA, Dib L, Yamout B, Sawaya R, Rahi AC, Fuleihan Gel H. Two randomized vitamin D trials in ambulatory patients on anticonvulsants: impact on bone. Neurology 67 2006; 2005-2014
    CrossrefPubMedGoogle Scholar
  • 71 Harden CL, Pulver MC, Ravdin L, Javobs AR. The effect of menopause and perimenopause on the course of epilepsy. Epilepsia 40 1999; 1402-1407
    CrossrefPubMedGoogle Scholar
  • 72 Dilip Gude. Epilepsy, anti-epileptic drugs and bone health in children. J Pediatr Neurosci 6 2011; 93
    PubMedGoogle Scholar
  • 73 Vinayan KP, Nisha B. Epilepsy, antiepileptic drugs and bone health. Ann Indian Acad Neurol 9 2006; 90-97
    CrossrefPubMedGoogle Scholar